TOOKAD Reduced Disease Worsening in Low-risk Prostate Cancer Patients After 4 Years, Study Found

TOOKAD Reduced Disease Worsening in Low-risk Prostate Cancer Patients After 4 Years, Study Found
Steba Biotech's TOOKAD treatment significantly reduces overall disease progression in men with low-risk prostate cancer, eliminating the need for most low-risk patients to undergo radical therapy, according to four-year follow-up data announced by the company. Results from the study, "Randomized Trial of Partial Gland Ablation with Vascular-Targeted Phototherapy versus Active Surveillance for Low-risk Prostate Cancer: Extended Follow-up and Analyses of Effectiveness," were published in the Journal of Urology. In some cases, prostate cancer is diagnosed as low-risk, meaning the tumor is small and growing at such a low rate that it's not viewed as life-threatening. These tumors do not warrant immediate treatment, such as radiotherapy or surgery, that could seriously impact the patient's quality of life. Instead, physicians usually recommend active surveillance (AS) or watchful waiting to monitor disease progression through regular checkups, including prostate-specific antigen (PSA) blood tests, digital rectal exams (DREs), and ultrasounds. However, studies have shown that 25% to 60% of men on AS eventually switch to radical therapy within five to 10 years. This prompted investigators to start looking for a more effective therapeutic option to control low-risk cancers that also posed minimal risks to patients' urinary, sexual, or bowel functions. Now, after a four-year follow-up period, researchers believe t
Subscribe or to access all post and page content.

One comment

  1. jimmy hodges says:

    i was daagnosed and biopsied 18 years ago,showed enlarged prostate,but negative for cancer,about 3 years ago another biopsy,it showed positive, the treatment suggested was wait and watch,this last biopsy being the only one since about 1997. my prostate number was 6. thank you very much, Jimmy

Leave a Comment

Your email address will not be published. Required fields are marked *